- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Biocon Group's Q3FY26 revenue grew 9% YoY to ₹ 4,173 Cr, with net profit surging 475% YoY to ₹ 144 Cr. Generics revenue jumped 24% (₹ 851 Cr) from new GLP-1 launches. Biosimilars rose 9% (₹ 2,497 Cr), boosting segment EBITDA by 44% with strong North America traction. CRDMO dipped 3% (₹ 917 Cr) due to a temporary client issue.
A key strategic move is integrating Biocon and Biocon Biologics to simplify structure, enhance financials, and leverage synergies across their diverse portfolio (biosimilars, insulins, GLPs) in high-need areas. Syngene (CRDMO) aims to capitalize on global outsourcing trends by expanding client relationships and capacity.
Biocon strengthened its balance sheet with a ₹ 4,500 Cr QIP, saving ~₹ 300 Cr annually in interest. Product launches are accelerating, including the first interchangeable biosimilar Aspart in the US, plus new GLP-1s, oncology, and immunology biosimilars. Major capex is largely complete; Generics received positive US FDA EIRs. Syngene extended its BMS partnership to 2035.
Net Debt/EBITDA improved to 2.8x (proforma 9M FY26) from 4.3x in FY23. Management expects sustainable growth from integration and a robust product pipeline targeting affordable global access. Major capex is finalized, positioning Biocon for demand for 5+ years. CRDMO anticipates improved capacity utilization.